Education
About Us
Working with TipRanks
Follow Us
DBV Technologies (GB:0QAJ)
LSE:0QAJ
0QAJ Stock Chart & Stats
€3.72
€0.09(13.42%)
At close: 4:00 PM EST
€3.72
€0.09(13.42%)
Day’s Range― - ―
52-Week Range€0.67 - €4.46
Previous CloseN/A
Volume68.68K
Average Volume (3M)14.50K
Market Cap
€1.05B
Enterprise Value€647.32M
Total Cash (Recent Filing)€69.84M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Mar 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding274,852,080
10 Day Avg. Volume25,717
30 Day Avg. Volume14,501
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.31
Price to Sales (P/S)15.24
P/FCF Ratio-0.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.50Price Target Upside47.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€4.09M
Bulls Say, Bears Say
Bulls Say
Proprietary EPIT PlatformDBV’s epicutaneous immunotherapy (EPIT) patch platform is a durable strategic asset: it targets a clear clinical niche (food allergies) with a non-invasive delivery mechanism that can be extended to other allergens. Platform breadth supports long-term product pipeline optionality if clinical progress continues.
Low Financial LeverageThe company’s negligible reported debt materially reduces solvency and interest-rate risk, giving management financing flexibility. For a clinical-stage biotech burning cash, low leverage preserves strategic options for funding trials or partnerships without immediate debt servicing constraints.
Recent Strong Gross MarginStronger recent gross margins indicate the company can achieve favorable manufacturing economics or pricing on its offerings. If sustained through commercialization, this improves the leverage of future revenue growth to profits and reduces the incremental cash required to scale product delivery.
Bears Say
Sharp Revenue DeclineA near-50% TTM revenue contraction signals weak commercial traction or concentrated revenue sources. Falling top line makes it harder to cover fixed R&D and SG&A, slows pathway to sustainable margins, and increases dependence on external funding or strategic partnerships.
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$98M TTM creates recurring external funding needs. Frequent financings can dilute shareholders, divert management attention, and constrain the company’s ability to invest selectively in late-stage trials or commercialization without securing new capital.
Deep Net Losses And Equity ErosionMaterial and persistent net losses (TTM net margin ~-52%) are eroding shareholder equity and return metrics. Continued negative profitability reduces strategic flexibility, raises governance scrutiny, and heightens risk that future value creation will require clinical success or transformational partnerships.
DBV Technologies News
0QAJ FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest share price was €0.67 and its highest was €4.46 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €1.05B.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Mar 05, 2026 which is in 5 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Oct 28, 2025. The company reported -€0.041 earnings per share for the quarter, beating the consensus estimate of -€0.055 by €0.014.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Undervalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.04.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 274,852,080 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.041 in its last earnings report, beating expectations of -€0.055. Following the earnings report the stock price went down -9.007%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in GB:0QAJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
0QAJ Stock 12 Month Forecast
Average Price Target
€5.50
▲(47.85% Upside)
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Sensorion SAS
―
Options Prices
Currently, No data available
---